Journal of Clinical and Translational Endocrinology最新文献

{"title":"Association of the time in targeted blood glucose range of 140 to 180 mg/dL with the mortality of critically ill patients with diabetes: analysis of the MIMIC-IV database","authors":"Huimin Ye ,&nbsp;Zilan Ma ,&nbsp;Qunchuan Zong ,&nbsp;Qiang Zhu ,&nbsp;Yufei Yan ,&nbsp;Shengmei Yang ,&nbsp;Pengyue Xiang ,&nbsp;Huajie Zou","doi":"10.1016/j.jcte.2025.100413","DOIUrl":"10.1016/j.jcte.2025.100413","url":null,"abstract":"<div><h3>Background</h3><div>Time in range (TIR), a glycemic control metric, is increasingly linked to diabetes outcomes. A target of 140–180 mg/dL is recommended for critically ill hyperglycemic patients.</div></div><div><h3>Methods</h3><div>This cohort study analyzed 6,047 critically ill diabetic patients (median age 68, 62.3 % male) from the MIMIC-IV database. TIR (140–180 mg/dL) was defined as the percentage of time within the target glucose range over 24 h. Patients were stratified by TIR quartiles. Outcomes included all-cause mortality, ICU mortality, in-hospital mortality, and 28-day mortality. Cox models assessed TIR-outcomes relationships.</div></div><div><h3>Results</h3><div>Higher TIR correlated with lower mortality. Adjusted HRs for all-cause mortality were 1.00 (Q1), 0.63 (Q2), 0.56 (Q3), and 0.65 (Q4) (<em>p</em> for trend &lt; 0.001). Similar trends were observed for in-hospital mortality (Q4 vs. Q1: HR 0.79, 95% CI: 0.64–0.97). Each 10 % TIR increase reduced all-cause mortality by 8 % (HR 0.92, 95 % CI: 0.88–0.95). Nonlinear dose–response relationships were significant (<em>p</em> &lt; 0.001), with stronger effects in patients &lt; 60, males, and those with myocardial infarction or cancer history (<em>p</em> for interaction &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Higher TIR (140–180 mg/dL) is associated with reduced mortality in critically ill diabetic patients, suggesting that TIR is a valuable metric for glycemic management in the ICU.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100413"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated glucose levels in melanoma patients − a real-world analysis","authors":"Joan Walter ,&nbsp;Bojan Bojanic ,&nbsp;Manuel Dittli ,&nbsp;Nadia Fehr ,&nbsp;Thomas Sartoretti ,&nbsp;Moritz Schwyzer ,&nbsp;Katharina Binz ,&nbsp;Antonio G. Gennari ,&nbsp;Matthias Ernst ,&nbsp;Martin W. Huellner ,&nbsp;Michael Messerli","doi":"10.1016/j.jcte.2025.100405","DOIUrl":"10.1016/j.jcte.2025.100405","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the glycemic status of consecutive melanoma patients undergoing standardized capillary fasting blood glucose (cFBG) assessment prior to fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) examination.</div></div><div><h3>Methods</h3><div>This retrospective study included 336 consecutive melanoma patients at the University Hospital Zurich, Switzerland. Fasting cFBG levels were measured prior to FDG PET/CT and classified according to American Diabetes Association guidelines. Multivariable linear regression analysis was performed to identify independent predictors of cFBG levels. Sensitivity analyses were performed on patients examined before 11 AM and fasting for 8 h as well as patients without known diabetes.</div></div><div><h3>Results</h3><div>The cohort included 336 melanoma patients with a median age of 67 years (IQR 57–76), 36 % female (122/336), and 12 % (40/336) with known diabetes mellitus. The median cFBG was 103 mg/dL (IQR 94–112; 5.7 mmol/L, IQR 5.2–6.2). Overall, 58 % (194/336) of patients had non-normal cFBG levels (≥100 mg/dL; ≥5.6 mmol/L), consistent with findings from a sensitivity analysis of patients presenting before 11 AM, where 58 % (115/198) exhibited non-normal levels. Excluding patients with known diabetes, 56 % (165/296) of patients had non-normal cFBG levels, with 7 % (20/210) having levels ≥126 mg/dL (≥7.0 mmol/L), indicative of possible undiagnosed diabetes mellitus. Multivariable linear regression analysis identified male gender, active disease, and subcutaneous fat as independent predictors of cFBG levels, whereas traditional risk factors such as BMI, visceral fat, hypertension or lack of exercise were not independent predictors.</div></div><div><h3>Conclusion</h3><div>More than half of melanoma patients have elevated cFBG levels, even in those without known diabetes, highlighting the need for improved glycemic screening and management.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100405"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting accelerated fetal growth in pregnancy: beyond maternal hyperglycemia – The role of prothymosin-α, inflammatory cytokines, and angiogenic factors","authors":"Maria Mirabelli ,&nbsp;Marta Greco ,&nbsp;Stefano Iuliano ,&nbsp;Francesco Dragone ,&nbsp;Eusebio Chiefari ,&nbsp;Daniela Foti ,&nbsp;Antonio Brunetti","doi":"10.1016/j.jcte.2025.100404","DOIUrl":"10.1016/j.jcte.2025.100404","url":null,"abstract":"<div><div><em>Aim</em>: This study investigates prothymosin-α (ProT-α), an immunomodulatory protein, as a potential biomarker for insulin resistance in gestational diabetes (GDM), and as a predictor of fetal growth by 20 weeks of gestation (wg). <em>Methods</em>: Forty-six women with singleton pregnancies were classified into GDM (n = 8) and normal glucose tolerance (NGT; n = 38) groups based on 75 g OGTT results. Maternal glucose, insulin, cytokines, and ProT-α levels were measured, and fetal growth was assessed by ultrasound at 20 wg, focusing on abdominal circumference (AC) and estimated fetal weight (EFW) percentiles. <em>Results</em>: Women with GDM were older, had a higher BMI, glucose, and insulin levels, with fetuses showing higher AC and EFW percentiles. IL-8, TNFα, and IL-1α were lower in the GDM group, while ProT-α was also lower but not significantly. ProT-α inversely correlated with EFW percentiles, independent of GDM. Regression analysis identified 2-hour post-load glucose, VEGF, and EGF as positive predictors of fetal growth acceleration, while IL-10 and ProT-α were negative predictors. <em>Conclusions</em>: Fetal growth is influenced by maternal glucose, inflammation, and angiogenesis. ProT-α may serve as an independent biomarker for predicting fetal growth in early pregnancy, suggesting further investigation into its role in GDM, obesity, and insulin resistance.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100404"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications","authors":"Jie Liu ,&nbsp;Yong Yao ,&nbsp;Lian Duan ,&nbsp;Lin Lu ,&nbsp;Huijuan Zhu ,&nbsp;Yongning Li ,&nbsp;Jun Gao","doi":"10.1016/j.jcte.2025.100408","DOIUrl":"10.1016/j.jcte.2025.100408","url":null,"abstract":"<div><div>Pituitary adenomas (PAs) are common brain tumors, accounting for about 15% of all brain neoplasms. Although generally benign, they can lead to serious complications through mass effects and hormone dysregulation. Emerging evidence suggests that collagen, a major component of the extracellular matrix (ECM), plays a pivotal role in PA pathophysiology. Collagen provides both structural integrity and biochemical cues within the tumor microenvironment (TME), influencing cellular behaviors and intercellular interactions. Recent studies indicate that collagen remodeling in PAs is dynamic, with alterations in collagen composition and organization affecting tumor growth, invasion, and hormone secretion. Collagen degradation products and collagenase activity may also facilitate tumor invasion into adjacent tissues. Additionally, collagen has been implicated in immune modulation, acting as a physical barrier that restricts immune cell infiltration and promotes immune evasion through receptor-mediated signaling. Metabolically, collagen may serve as an energy source or modulate metabolic pathways to sustain tumor proliferation. Clinically, collagen content in PAs correlates with tumor consistency, which has implications for surgical resection strategies. Moreover, serum collagen is emerging as a potential non-invasive biomarker for PA diagnosis and prognosis. Targeting collagen synthesis, degradation, or its mechanotransductive signaling pathways represents a promising therapeutic avenue.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100408"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144614279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between cardiometabolic index and sarcopenia: 2011–2018 National Health and Nutrition Examination survey (NHANES)","authors":"Yi Shen,&nbsp;Jiayu Zhang,&nbsp;Xiuyue Qiu","doi":"10.1016/j.jcte.2025.100415","DOIUrl":"10.1016/j.jcte.2025.100415","url":null,"abstract":"<div><h3>Background</h3><div>The cardiometabolic index (CMI) is a reliable marker used to assess the degree of obesity and lipid metabolism disorders in individuals. Emerging evidence indicates that disorders of lipid metabolism and sarcopenia share a common pathophysiologic basis. However, few studies have investigated the association between CMI and sarcopenia. Therefore, this study aimed to find the possible correlation between CMI and sarcopenia.</div></div><div><h3>Methods</h3><div>This study used cross-sectional research methods to investigate data on CMI, sarcopenia, and other covariates among participants in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018. We explored the relationship between CMI and sarcopenia through multivariate linear and logistic regression, and we performed sensitivity and subgroup analyses. Also, receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were utilized to evaluate the performance of CMI in identifying sarcopenia.</div></div><div><h3>Results</h3><div>Of the 4,808 adults aged 20 to 59 included in this study, 428 (8.90 %) were identified as having sarcopenia. A significant nonlinear association between CMI and sarcopenia was demonstrated in a generalized additive model (GAM). After inclusion of all covariates, CMI showed a significant association with the prevalence of sarcopenia (OR = 1.173(1.086–1.267), <em>P</em> &lt; 0.001). CMI got an AUC of 0.69 in identifying sarcopenia. Finally, subgroup analyses showed that the association between CMI and sarcopenia was particularly pronounced in individuals who differed in marital status, poverty-to-income ratio, alcohol consumption, patients without diabetes, and patients with hypertension (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>This study demonstrated that an elevated CMI was associated with an increased prevalence of sarcopenia. The finding suggests that CMI could serve as a potential marker for sarcopenia, highlighting the need for further research to explore the relationship between dyslipidemia and sarcopenia.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100415"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The CuPeR model: A dynamic online tool for predicting Cushing’s disease persistence and recurrence after pituitary surgery","authors":"Guive Sharifi ,&nbsp;Elham Paraandavaji ,&nbsp;Nader Akbari Dilmaghani ,&nbsp;Tohid Emami Meybodi ,&nbsp;Ibrahim Mohammadzadeh ,&nbsp;Neginalsadat Sadeghi ,&nbsp;Amirali Vaghari ,&nbsp;Behnaz Niroomand ,&nbsp;Seyed Mohammad Tavangar ,&nbsp;Mohammad reza Mohajeri Tehrani ,&nbsp;Zahra Davoudi ,&nbsp;Marjan Mirsalehi ,&nbsp;Seyed Ali Mousavinejad ,&nbsp;Farzad Taghizadeh-Hesary","doi":"10.1016/j.jcte.2025.100417","DOIUrl":"10.1016/j.jcte.2025.100417","url":null,"abstract":"<div><h3>Objective</h3><div>Predicting postoperative persistence and recurrence of Cushing’s disease (CD) remains a clinical challenge, with no universally reliable models available. This study introduces the CuPeR model, an online dynamic nomogram developed to address these gaps by predicting postoperative outcomes in patients with CD undergoing pituitary surgery.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 211 patients treated for CD between 2010 and 2024 was analyzed. Key patient and tumor characteristics, imaging findings, and treatment details were evaluated. Multivariate logistic regression identified independent predictors of postoperative persistence or recurrence of CD (PoRP-CD), which were then incorporated into the CuPeR model using stepwise selection based on Akaike Information Criterion. Internal validation was performed using a testing dataset, and a user-friendly online nomogram was developed to facilitate immediate, patient-specific risk estimation in clinical practice.</div></div><div><h3>Results</h3><div>The final predictive model identified four key factors: symptom duration, MRI Hardy’s grade, tumor site, and prior pituitary surgery. Longer symptom duration and a history of prior surgery significantly increased the risk of recurrence, while bilateral tumor location reduced this risk. The model demonstrated an area under the receiver operating characteristic curve (AUC-ROC) of 0.70, with 83% accuracy, specificity of 96%, and sensitivity of 33%.</div></div><div><h3>Conclusions</h3><div>The CuPeR model may offer a practical tool for predicting PoRP-CD, enhancing preoperative decision-making by providing personalized risk assessments.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100417"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender differences in psychosocial outcomes according to BMI among adults living with type 1 diabetes: A cross-sectional BETTER analysis","authors":"Anne Bonhoure ,&nbsp;Marie-Laure Lalanne-Mistrih ,&nbsp;Meryem Talbo ,&nbsp;Valérie Boudreau ,&nbsp;Virginie Messier ,&nbsp;Aude Bandini ,&nbsp;Laurence Secours ,&nbsp;Sonia Fontaine ,&nbsp;Anne-Sophie Brazeau ,&nbsp;Rémi Rabasa-Lhoret","doi":"10.1016/j.jcte.2025.100400","DOIUrl":"10.1016/j.jcte.2025.100400","url":null,"abstract":"<div><h3>Aims</h3><div>The prevalence of overweight and obesity in people with type 1 diabetes has increased significantly, presenting additional psychosocial challenges that vary by gender. This study investigates the relationship between BMI and psychosocial outcomes in adult men and women with type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cross-sectional analysis used data from people with type 1 diabetes in the BETTER registry, stratified by gender and categorized into BMI groups (&lt;25, 25–29.9, ≥ 30 kg/m²). Psychosocial outcomes included depression, diabetes distress, and stigmatization related to diabetes. One-way ANOVA assessed differences between BMI groups by gender. Multivariable logistic regression then analyzed gender differences within each BMI group, adjusting for age and HbA1c.</div></div><div><h3>Results</h3><div>Among 1028 participants (66 % women, mean BMI 26.4 ± 5.1 kg/m², mean age 45.4 ± 15.0 years), 460 adults (45 %) had a BMI &lt; 25, 356 (35 %) between 25–29.9, and 212 (21 %) ≥ 30 kg/m². Women in the ≥ 30 kg/m² group, compared to the &lt; 25 kg/m² group, had more symptoms of depression, more drug prescriptions for depression/anxiety, and higher diabetes distress (p &lt; 0.001 for all). In men, psychosocial outcomes did not differ significantly across BMI groups. Multivariable regression showed women were more likely than men to report prescriptions for depression/anxiety and high diabetes distress, particularly in the higher BMI groups.</div></div><div><h3>Conclusions</h3><div>In adults living with type 1 diabetes, higher BMI is associated with adverse psychosocial outcomes, particularly in women. Gender-specific interventions addressing mental health, stigma, and weight management could be beneficial to improve overall well-being.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100400"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enrollment in a fracture liaison service does not guarantee post fracture follow-up","authors":"Craig R. Jenkins,&nbsp;Jessica D. Collier,&nbsp;Claire I. Yee,&nbsp;Blake T. Langlais,&nbsp;Jaxon K. Quillen,&nbsp;Patricia M. Verona,&nbsp;Michael D. Whitaker,&nbsp;Curtiss B. Cook","doi":"10.1016/j.jcte.2025.100409","DOIUrl":"10.1016/j.jcte.2025.100409","url":null,"abstract":"<div><h3>Objective</h3><div>To assess post fracture outpatient follow-up adherence in a cohort of patients enrolled in a fracture liaison service (FLS).</div></div><div><h3>Methods</h3><div>We analyzed FLS registry data for patients who were hospitalized with fragility fractures from June 2020 through December 2022 and determined the proportion of patients who kept their follow-up appointments in outpatient endocrinology and orthopedic clinics.</div></div><div><h3>Results</h3><div>We identified 295 patients who were eligible for the FLS pathway; from this group, 57 declined an endocrinology follow-up visit. Of the remaining 238 patients, 95 (40 %) had appointments but subsequently canceled and 7 (3 %) did not show up for their appointments. No follow-up information was documented for 77 patients (32 %). Thus, only 59 of 238 (25 %) kept their appointments in endocrinology. In the univariate analyses, age, severity of illness, and discharge status were associated with follow-up adherence only in the orthopedic cohort (<em>P</em> ≤ 0.02). However, the adjusted analyses did not identify any variables that were associated with follow-up adherence in either the endocrinology or orthopedic cohorts.</div></div><div><h3>Conclusion</h3><div>Post fracture outpatient follow-up was lower for the endocrinology cohort, as compared with the orthopedic cohort, even among patients enrolled in an FLS. Factors that were previously postulated to influence follow-up, including those described in this study, showed no association with appointment-keeping behavior. Possibly, the importance of osteoporosis treatment is not emphasized or the treatment options are unappealing to our patient population. Further study is needed to determine the specific obstacles contributing to the low endocrine post fracture follow-up rate.</div></div><div><h3>Key Message</h3><div>Fracture liaison services can reliably reduce future fracture events, but follow-up adherence after hospitalization remains challenging. We compared the rates of endocrinology vs orthopedic follow-up in a single cohort of patients hospitalized for fragility fractures and assessed variables that potentially contributed to the lower endocrinology follow-up rate (eg, travel distance, age, marital status). However, no factors were identified as having a significant effect. These data show that the specific obstacles previously thought to contribute to lower-than-expected post fracture follow-up rates are misleading, and novel approaches are needed to address this widespread issue.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100409"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild hyperprolactinemia in women with polycystic ovary syndrome. Insights from a large cross-sectional study","authors":"Manuel Luque-Ramírez,&nbsp;Alejandra Quintero-Tobar,&nbsp;María Ángeles Martínez-García,&nbsp;Sara de Lope Quiñones,&nbsp;María Insenser,&nbsp;Lía Nattero-Chávez,&nbsp;Héctor Francisco Escobar-Morreale","doi":"10.1016/j.jcte.2025.100412","DOIUrl":"10.1016/j.jcte.2025.100412","url":null,"abstract":"<div><h3>Background</h3><div>Hyperprolactinemia is an exclusion criterion for polycystic ovary syndrome (PCOS), albeit PCOS itself is argued to induce mild hyperprolactinemia. We aimed to study the prevalence and causes of hyperprolactinemia in patients with PCOS.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study including 336 premenopausal patients with PCOS and 90 nonhyperandrogenic controls referred to our clinics (referral population). We also studied an unselected population of premenopausal individuals who attended our center for voluntary blood donation (14 patients with PCOS and 207 non-hyperandrogenic controls). The main outcome measure was the percentage of individuals with hyperprolactinemia.</div></div><div><h3>Results</h3><div>As a whole, 39 out of 647 participants showed increased basal prolactin concentrations (6.0%, 95%CI: 4.4; 8.1) regardless of having PCOS or being a control, in both referral and unselected populations. In the referral population, 18 out of 31 individuals with hyperprolactinemia (58.0%, 95%CI: 40.8; 73.6) showed normal prolactin concentrations after appropriate resting, suggesting venipuncture stress-related hyperprolactinemia, and another nine participants (29.0%, 95%IC: 16.1; 46.6) did so after pre-analytical polyethylene-glycol precipitation of serum, indicating macroprolactinemia. There were differences in these figures between patients with PCOS and controls. In the unselected population, three out of eight participants with hyperprolactinemia (37.5%, 95%IC: 13.7; 69.4) had macroprolactinemia, and stress-related hyperprolactinemia accounted for another 62.5% (95%IC: 30.6; 86.3) of cases.</div></div><div><h3>Conclusions</h3><div>Hyperprolactinemia is equally likely among patients with PCOS and non-hyperandrogenic individuals. The most common causes of mild hyperprolactinemia in this population are venipuncture stress and macroprolactinemia that must not preclude a diagnosis of PCOS if suggested by signs and symptoms.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100412"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoids: The culprit behind metabolic disorders in primary Aldosteronism? A narrative review","authors":"Piotr Kmieć ,&nbsp;Renata Świątkowska-Stodulska","doi":"10.1016/j.jcte.2025.100401","DOIUrl":"10.1016/j.jcte.2025.100401","url":null,"abstract":"<div><div>In recent years, a new approach toward aldosterone secretion autonomy has emerged as a consequence of studies demonstrating its continuum from subclinical, mild to overt and severe forms. These clinical insights were accompanied by immense progress in deciphering the tissue and cellular pathology underlying primary aldosteronism (PA).</div><div>Thus far, research has not sufficiently elucidated the relationships between overt PA and metabolic disorders. Similarly, the role of glucocorticoid cosecretion in this patient group remains unclear. Milder than overt PA forms have been scarcely investigated.</div><div>This review critically analyzes these issues on the basis of a literature search of the PubMed database.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100401"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144169423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}